Companies sponsors |
Boehringer Ingelheim Ltd (spesolimab) |
Others |
Department of Health and Social Care |
|
NHS England |
Patient carer groups |
Changing Faces |
|
Gene People |
|
Genetic Alliance UK |
|
Psoriasis and Psoriatic Arthritis Alliance |
|
Psoriasis Association |
|
Psoriasis Help Organisation |
|
South Asian Health Foundation |
|
Specialised Healthcare Alliance |
Professional groups |
Association of Genetic Nurses & Counsellors |
|
British Association of Dermatologists |
|
British Dermatological Nursing Group |
|
British Geriatrics Society |
|
British Society for Cutaneous Allergy |
|
British Society for Genetic Medicine |
|
Primary Care Dermatology Society |
|
Royal College of General Practitioners |
|
Royal College of Nursing |
|
Royal College of Pathologists |
|
Royal College of Physicians |
|
Royal Pharmaceutical Society |
|
Royal Society of Medicine |
|
St John’s Institute of Dermatology |
|
UK Clinical Pharmacy Association |
Associated public health groups |
Public Health Wales |
|
UK Health Security Agency |
Comparator companies |
AbbVie (adalimumab, risankizumab) |
|
Accord Healthcare (methotrexate) |
|
Advanz Pharma (methotrexate) |
|
Almirall (dimethyl fumarate, tildrakizumab) |
|
Amgen (adalimumab, apremilast) |
|
Aspire Pharma (dimethyl fumarate) |
|
Biogen Idec (adalimumab, dimethyl fumarate, etanercept, infliximab) |
|
Bristol Myers Squibb (deucravacitinib) |
|
B&S Colorama (ciclosporin) |
|
Celltrion Healthcare UK (adalimumab, infliximab) |
|
Celix Pharma (dimethyl fumarate) |
|
Dexcel-Pharma (ciclosporin) |
|
Eli Lilly and Company (ixekizumab) |
|
Fresenius Kabi (adalimumab) |
|
Genus Pharmaceuticals (acitretin, dimethyl fumarate) |
|
Hospira UK (methotrexate) |
|
Johnson & Johnson Innovative Medicine (guselkumab, ustekinumab) |
|
Leo Pharma (brodalumab) |
|
Medac GmbH (methotrexate) |
|
Merck Sharp & Dohme (infliximab) |
|
Morningside Healthcare (acitretin, ciclosporin, methotrexate) |
|
Mylan (ciclosporin, dimethyl fumarate) |
|
Nordic Pharma (methotrexate) |
|
Novartis Pharmaceuticals UK (ciclosporin, secukinumab) |
|
Orion Pharma (UK) (methotrexate) |
|
Pfizer (etanercept, infliximab, methotrexate) |
|
Rosemont Pharmaceuticals (methotrexate) |
|
Sandoz (adalimumab, etanercept, infliximab, methotrexate) |
|
Santen UK (ciclosporin) |
|
Teva UK (acitretin, ciclosporin, methotrexate) |
|
Therakind Limited (methotrexate) |
|
UCB Pharma (bimekizumab, certolizumab pegol) |
|
Viatris (ciclosporin) |
|
Wockhardt (dimethyl fumarate) |
|
Zentiva (dimethyl fumarate) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
Allied Health Professionals Federation |
|
Board of Community Health Councils in Wales |
|
British National Formulary |
|
Care Quality Commission |
|
Department of Health - Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
National Association of Primary Care |
|
National Pharmacy Association |
|
NHS Confederation |
|
Scottish Medicines Consortium |
|
Welsh Government |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
British Skin Foundation |
|
Centre of Evidence-based Dermatology, University of Nottingham |
|
Cochrane Skin Group |
|
Dermatrust |
|
Genomics England |
|
MRC Clinical Trials Unit |
|
National Institute for Health Research |